2022 No. 5

2022 No.5

Theme Issue: New Progress in the Treatment of Hepatobiliary Tumors in the New Era of Immunotherapy

Executive Chief Editor: ZHOU Jian

Zhongshan Hospital Affiliated to Fudan University

Cover Content

Previous Issue | Next Issue

Select articles

Display Method:

Editorial

Opportunities and challenges for the treatment of malignant hepatobiliary tumors in the new era of immunotherapy

Xiaoyong HUANG, Guoming SHI, Jian ZHOU

2022, 38(5): 977-979. DOI: 10.3969/j.issn.1001-5256.2022.05.001

Abstract(1142)

HTML (369)

PDF (1944KB)(227) Cited By (6)

Abstract:
Malignant hepatobiliary tumors mainly include hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) and are common malignancies in China that seriously threaten the life and health of the Chinese people. Malignant hepatobiliary tumors often have an insidious onset, and most patients have los...

Discussions by Experts

Perioperative immunotherapy for hepatocellular carcinoma

Bin XU, Meiling LI, Huichuan SUN

2022, 38(5): 980-984. DOI: 10.3969/j.issn.1001-5256.2022.05.002

Abstract(1097)

HTML (489)

PDF (1893KB)(197) Cited By (6)

Abstract:
Hepatocellular carcinoma (HCC) greatly threatens the life and health of Chinese people. Most patients with HCC are already in the advanced stage when attending the hospital and are not eligible for radical treatment, and patients in the early stage of HCC who are eligible for radical treatment still...

Adverse reactions associated with immune checkpoint inhibitor in treatment of liver cancer and related treatment measures

Hanping WANG

2022, 38(5): 985-991. DOI: 10.3969/j.issn.1001-5256.2022.05.003

Abstract(1624)

HTML (386)

PDF (1918KB)(261) Cited By (14)

Abstract:
Immune checkpoint inhibitors (ICIs) exert a therapeutic effect on liver cancer by enhancing the body's anti-tumor immunity and have become an important treatment method in the field of liver cancer. However, while ICIs activate the anti-tumor immunity, they also bring a series of special toxic and s...

Advances in targeted therapy combined with immunotherapy for advanced hepatocellular carcinoma

Xiufeng LIU, Jue ZHANG, Lin YAO, Chaoxu YANG

2022, 38(5): 992-997. DOI: 10.3969/j.issn.1001-5256.2022.05.004

Abstract(1704)

HTML (489)

PDF (3145KB)(212) Cited By (8)

Abstract:
The IMbrave 150 study opened the door of immunotherapy combined with targeted therapy, and then the data of ORIENTAL-32, a Phase Ⅲ clinical trial for Chinese patients, was released, which confirmed the efficacy of immunotherapy combined with targeted therapy, especially significant survival benefits...

Immune checkpoint inhibitors for treatment of biliary malignant tumors

Guoming SHI, Yanzhi PEI, Pinxiang LU, Jun CAO, Jian ZHOU, Jia FAN

2022, 38(5): 998-1001. DOI: 10.3969/j.issn.1001-5256.2022.05.005

Abstract(961)

HTML (281)

PDF (1877KB)(147) Cited By (2)

Abstract:
Biliary malignant tumors have an insidious onset and rapid development, and most patients have lost the opportunity for radical surgery at initial diagnosis and often have poor prognosis. Gemcitabine-based chemotherapy is the first-line treatment for biliary malignant tumors, but with a limited clin...

Hotspot·Perspective·Viewpoint

Liver cirrhosis: Decompensation and "recompensation"

Zhiying HE, Bingqiong WANG, Hong YOU

2022, 38(5): 1002-1005. DOI: 10.3969/j.issn.1001-5256.2022.05.006

Abstract(1991)

HTML (2003)

PDF (1882KB)(385) Cited By (13)

Abstract:
The evolution concept of decompensated cirrhosis rebuilds the clinical staging system for decompensated cirrhosis, which changes the focus from the pattern of disease progression to refining the status of acute decompensation onset and proposing "recompensation" of decompensated cirrhosis. During th...

Guidelines

Standard for diagnosis and treatment of pancreatic cancer (2022 edition)

General Office of National Health Commission

2022, 38(5): 1006-1015. DOI: 10.3969/j.issn.1001-5256.2022.05.007

Abstract(3296)

HTML (4952)

PDF (2008KB)(1316) Cited By (181)

Abstract:

Chinese consensus on the early screening and surveillance for pancreatic cancer in high-risk individuals (2021, Nanjing)

Pancreatic Disease Collaborative Group, Chinese Society of Digestive Endoscopy

2022, 38(5): 1016-1022. DOI: 10.3969/j.issn.1001-5256.2022.05.008

Abstract(1626)

HTML (318)

PDF (3080KB)(346) Cited By (17)

Abstract:
Pancreatic cancer is highly malignant with a low five-year survival rate, which is caused by the difficulties in early diagnosis. At present, there is still no standardized procedure for the early screening for pancreatic cancer in China. With reference to related research advances in China and glob...

An excerpt of Asian Pacific Association for the Study of Liver (APASL) guidelines: Hepatitis B virus in pregnancy (2022)

Chao CHEN, Chenxu WANG, Guanlun ZHOU, Yuhao JU, Deping YUAN, Xiajun YE, Guorong HAN

2022, 38(5): 1023-1026. DOI: 10.3969/j.issn.1001-5256.2022.05.009

Abstract(959)

HTML (182)

PDF (1871KB)(155) Cited By (3)

Abstract:

Guideline Interpretation

Interpretation of Standard for diagnosis and treatment of primary liver cancer (2022 edition)

Zhao LI, Jiye ZHU

2022, 38(5): 1027-1029. DOI: 10.3969/j.issn.1001-5256.2022.05.010

Abstract(1691)

HTML (277)

PDF (1893KB)(558) Cited By (61)

Abstract:

Original Articles_Viral Hepatitis

Value of HBsAg level in predicting liver inflammation in patients with HBeAg-positive chronic hepatitis B virus infection and normal alanine aminotransferase

Zhan ZENG, Yuanjiao GAO, Xiaoyue BI, Fengxin CHEN, Wen DENG, Tingting JIANG, Yanjie LIN, Liu YANG, Minghui LI, Yao XIE

2022, 38(5): 1030-1034. DOI: 10.3969/j.issn.1001-5256.2022.05.011

Abstract(936)

HTML (230)

PDF (1912KB)(76) Cited By (10)

Abstract:
Objective To investigate the onset of liver inflammation and related predictive factors in patients with HBeAg-positive chronic hepatitis B virus (HBV) infection who have normal alanine aminotransferase (ALT) and a high viral load. Methods A retrospective analysis was performed for the clinical data...

Comparison of two quantitative real-time PCR methods for serum HBV RNA in patients with HBeAg-positive chronic hepatitis B: A propensity score matching study

Yang WANG, Hao LIAO, Zhongping DENG, Dandan BIAN, Yan REN, Yingying JIANG, Shuang LIU, Yu CHEN, Fengmin LU, Zhongping DUAN, Sujun ZHENG

2022, 38(5): 1035-1040. DOI: 10.3969/j.issn.1001-5256.2022.05.012

Abstract(902)

HTML (169)

PDF (2241KB)(66) Cited By (6)

Abstract:
Objective To investigate the consistency between Shengxiang (S) and Xinbo (X) real-time PCR methods in the quantification of HBV RNA. Methods In the prospective follow-up cohort of 108 chronic hepatitis B (CHB) patients established from July 2007 to August 2008, 20 patients with HBeAg seroconversion...

Risk factors for osteopenia/osteoporosis and the diagnostic value of CT value in patients with chronic hepatitis B

Jingyi ZHANG, Yingmei TANG, Jiaqi LI, Qian WANG, Chenrui ZHANG

2022, 38(5): 1041-1047. DOI: 10.3969/j.issn.1001-5256.2022.05.013

Abstract(620)

HTML (286)

PDF (2526KB)(51) Cited By (4)

Abstract:
Objective To investigate the value of the CT values of thoracolumbar vertebrae measured by abdominal CT in the diagnosis of osteopenia/osteoporosis in patients with chronic hepatitis B, as well as the risk factors for osteopenia/osteoporosis in such patients. Methods A retrospective analysis was per...

Determination of a reasonable threshold of total bilirubin for the diagnosis of hepatitis B virus-associated acute-on-chronic liver failure

Hongmin WANG, Jingjing TONG, Xiang XU, Jing CHEN, Zifeng LIU, Haibin SU, Xiaoyan LIU, Jinhua HU

2022, 38(5): 1048-1052. DOI: 10.3969/j.issn.1001-5256.2022.05.014

Abstract(573)

HTML (186)

PDF (2361KB)(46) Cited By (5)

Abstract:
Objective To investigate a reasonable threshold of total bilirubin for the diagnosis of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF), and to realize accurate early diagnosis. Methods A retrospective analysis was performed for the clinical data of 1232 patients with HBV-ACLF wh...

Influence of artificial liver support system therapy on platelet in treatment of hepatitis B virus-related acute-on-chronic liver failure

Lu WANG, Wenxiong XU, Shu ZHU, Xuejun LI, Yuanli CHEN, Chan XIE, Liang PENG

2022, 38(5): 1053-1058. DOI: 10.3969/j.issn.1001-5256.2022.05.015

Abstract(764)

HTML (222)

PDF (2341KB)(62) Cited By (9)

Abstract:
Objective To investigate the changing trend of platelet count (PLT) and related influencing factors in patients with hepatitis B virus-related chronic-on-acute liver failure (HBV-ACLF) after artificial liver support system (ALSS) therapy. Methods A total of 152 patients with HBV-ACLF who were hospit...

Influencing factors for direct-acting antiviral therapy failure in treatment of hepatitis C

Yuqing YANG, Jia SHANG, Chengzhen LU, Song YANG, Hongyu CHEN, Jiali PAN, Yifan HAN, Hongli XI, Qian KANG, Ning TAN, Xiaoyuan XU

2022, 38(5): 1059-1063. DOI: 10.3969/j.issn.1001-5256.2022.05.016

Abstract(670)

HTML (147)

PDF (2180KB)(65) Cited By (4)

Abstract:
Objective To investigate the influencing factors for direct-acting antiviral agent (DAA) therapy failure in the treatment of hepatitis C by comparing baseline clinical data and resistance-associated substitution (RAS) in sequencing data between the patients with HCV RNA reactivation after DAA therap...

Original Articles_Fatty Liver Diseases

Value of triglyceride-glucose index and body mass index in predicting nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus

Dongxu WANG, Nan NAN, Hao BING, Lianjie LIN

2022, 38(5): 1064-1068. DOI: 10.3969/j.issn.1001-5256.2022.05.017

Abstract(727)

HTML (495)

PDF (2162KB)(61) Cited By (8)

Abstract:
Objective To investigate the value of triglyceride-glucose index (TyG) and body mass index (BMI) in predicting nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM). Methods A retrospective analysis was performed for the clinical data of 349 patients with T2DM who were treated ...

Effect of Quzhi Ruangan prescription on the farnesoid X receptor-fibroblast growth factor 19 pathway in rats with nonalcoholic steatohepatitis

Enrui XIA, Gege TIAN, Suyan ZHANG, Shunzhen ZHANG

2022, 38(5): 1069-1074. DOI: 10.3969/j.issn.1001-5256.2022.05.018

Abstract(685)

HTML (186)

PDF (4176KB)(41) Cited By (6)

Abstract:
Objective To investigate the effect of Quzhi Ruangan prescription on the farnesoid X receptor (FXR)-fibroblast growth factor 19 (FGF19) pathway in rats with nonalcoholic steatohepatitis (NASH). Methods Male Sprague-Dawley rats were randomly divided into normal group (Control group with 8 rats), mode...

Original Articles_Liver Fibrosis and Liver Cirrhosis

Effect of endoscopic ligation combined with traditional Chinese medicine syndrome differentiation-based treatment in the secondary prevention of esophageal variceal bleeding in patients with liver cirrhosis

Chong CHEN, Ying LYU, Xilei CHEN, Chenghai LIU, Ping LIU, Yongping MU

2022, 38(5): 1075-1080. DOI: 10.3969/j.issn.1001-5256.2022.05.019

Abstract(1043)

HTML (227)

PDF (1909KB)(53) Cited By (14)

Abstract:
Objective To investigate the efficacy of endoscopic ligation combined with traditional Chinese medicine (TCM) syndrome differentiation-based treatment in the secondary prevention of esophageal variceal bleeding (EVB) in patients with liver cirrhosis. Methods A total of 108 EVB patients who were admi...

Characteristic manifestations of ΔCT in hepatitis B cirrhosis with upper gastrointestinal bleeding and establishment of a predictive model

Junjie LI, Yanyan SUN, Jianghong LI, Hong ZHENG

2022, 38(5): 1081-1085. DOI: 10.3969/j.issn.1001-5256.2022.05.020

Abstract(612)

HTML (174)

PDF (2671KB)(39) Cited By (12)

Abstract:
Objective To investigate the CT characteristics of hepatitis B cirrhosis, and to predict the risk of bleeding by establishing a predictive model for upper gastrointestinal bleeding in liver cirrhosis. Methods A retrospective analysis was performed for the clinical data of 101 patients with hepatitis...

Original Articles_Liver Neoplasms

Efficacy and safety of programmed death-1 inhibitor combined with transarterial chemoembolization and anti-angiogenic drugs in treatment of advanced hepatocellular carcinoma

Xiaopeng DING, Jun TIE, Jiahao YU, Pengwei REN, Guoyun XUAN, Shuoyi MA, Changcun GUO, Ying HAN, Xinmin ZHOU

2022, 38(5): 1086-1091. DOI: 10.3969/j.issn.1001-5256.2022.05.021

Abstract(726)

HTML (198)

PDF (2633KB)(65) Cited By (10)

Abstract:
Objective To investigate the efficacy and safety of programmed death receptor-1 (PD-1) inhibitor combined with transarterial chemoembolization (TACE) and anti-angiogenic drug tyrosine kinase inhibitor (TKI) versus TACE combined with TKI in the treatment of advanced hepatocellular carcinoma (HCC) and...

Standardized establishment and informationized management of liver cancer biobank

Jingjing YU, Wei XIAO, Yani LI, Bixiang ZHANG, Xiaoping CHEN, Chang SHU

2022, 38(5): 1092-1096. DOI: 10.3969/j.issn.1001-5256.2022.05.022

Abstract(994)

HTML (309)

PDF (2538KB)(66) Cited By (4)

Abstract:
Objective To establish a small liver cancer biobank with a standard operating procedure and the function of informationized management. Methods According to the inclusion and exclusion criteria, blood, tissue, and stool samples were collected from the patients with liver cancer who attended Liver Su...

Original Articles_Other Liver Diseases

A preliminary study on the peripheral seroimmunological characteristics of drug-induced liver injury

Yu WANG, Qiong LUO, Shu LI, Xiaoping SHEN, Shuang LI, Yanyan TAO, Chenghai LIU

2022, 38(5): 1097-1100. DOI: 10.3969/j.issn.1001-5256.2022.05.023

Abstract(571)

HTML (150)

PDF (1881KB)(55) Cited By (5)

Abstract:
Objective To investigate the characteristic manifestation of the peripheral seroimmunological indicators such as cellular immunity and cytokines in drug-induced liver injury (DILI). Methods The medical records of 219 patients with DILI collected in Shuguang Hospital and Baoshan Branch from January 2...

Effect of exosomes from adult human liver-derived stem cells on concanavalin A-induced acute liver injury in mice

Luxiang HAN, Huixin TANG, Zhenfeng ZHAO, Shanshan LI, Quanyi WANG, Lingbin KONG, Huiying BI, Zhenfeng SHU, Zhongping DUAN, Yu CHEN, feng HONG

2022, 38(5): 1101-1105. DOI: 10.3969/j.issn.1001-5256.2022.05.024

Abstract(667)

HTML (199)

PDF (4326KB)(38)

Abstract:
Objective To investigate the protective effect of adult human liver-derived stem cell exosomes (HLSC-exo) intravenously injected at different time points against acute liver injury induced by concanavalin A (ConA) in mice. Methods HLSC-exo was extracted by differential centrifugation. Western blot w...

Original Articles_Pancreatic Diseases

Short-term efficacy and safety of Da Vinci robotic pancreaticoduodenectomy versus traditional laparoscopic pancreaticoduodenectomy: A meta-analysis

Xin DAI, Hanlin LIU, Qiang WANG, Peng SHU, Long CHENG, Tao WANG

2022, 38(5): 1106-1113. DOI: 10.3969/j.issn.1001-5256.2022.05.025

Abstract(999)

HTML (275)

PDF (3979KB)(48) Cited By (14)

Abstract:
Objective To systematically evaluate the short-term efficacy and safety of robotic pancreaticoduodenectomy (RPD) versus traditional laparoscopic pancreaticoduodenectomy (LPD), and to provide a reference for clinical research and practice. Methods Chinese and English databases such as PubMed, Embase,...

Case Reports

A case of primary biliary cholangitis with megaloblastic anemia

Mei CHEN, Ning MA, Jingbo JIN, Yu PENG, Sitong FAN, Fang WANG

2022, 38(5): 1114-1115. DOI: 10.3969/j.issn.1001-5256.2022.05.026

Abstract(871)

HTML (218)

PDF (2312KB)(55) Cited By (1)

Abstract:

Hepatic paragonimiasis diagnosed by liver histopathology: A case report

Yang LIU, Zhaoxia LI, Tong WU, Jiahe SHI, Ge YU, Guijie XIN

2022, 38(5): 1116-1118. DOI: 10.3969/j.issn.1001-5256.2022.05.027

Abstract(552)

HTML (295)

PDF (2302KB)(48) Cited By (2)

Abstract:

A case of hepatolenticular degeneration with hepatocellular carcinoma

Shaoxuan LUO, Ya LI, Feng XU

2022, 38(5): 1119-1121. DOI: 10.3969/j.issn.1001-5256.2022.05.028

Abstract(517)

HTML (138)

PDF (2067KB)(43) Cited By (1)

Abstract:

A rare ATP7B genotype identified in the siblings with hepatolenticular degeneration and their pedigree analysis

Jie ZHOU, Jinmao LIAO, Ling LIAO, Huanchun YANG, Zhan LIU

2022, 38(5): 1122-1125. DOI: 10.3969/j.issn.1001-5256.2022.05.029

Abstract(559)

HTML (123)

PDF (1871KB)(34) Cited By (3)

Abstract:

IgG4-related retroperitoneal fibrosis: A case report

Zhaoxia LI, Yang LIU, Nan LI, Zhuhui JI, Guijie XIN

2022, 38(5): 1126-1128. DOI: 10.3969/j.issn.1001-5256.2022.05.030

Abstract(547)

HTML (214)

PDF (2161KB)(48) Cited By (1)

Abstract:

Spontaneous rupture of biliary dilatation with cancer: A case report

Xiaotong QIU, Zhengqi WU, Yushi CAO, Xuxiang XIA, Guoyue LYU

2022, 38(5): 1129-1130. DOI: 10.3969/j.issn.1001-5256.2022.05.031

Abstract(559)

HTML (227)

PDF (2537KB)(25)

Abstract:

Gallbladder perforation with gastric perforation: A case report

Xiuping LUO, Peng PENG, Shiquan LIU, Mengbin QIN, Jiean HUANG

2022, 38(5): 1131-1133. DOI: 10.3969/j.issn.1001-5256.2022.05.032

Abstract(889)

HTML (215)

PDF (2333KB)(44) Cited By (2)

Abstract:

Vater ampulla neuroendocrine tumor with gastrointestinal stromal tumor: A case report

Zhengqi WU, Xiaotong QIU, Guoyue LYU

2022, 38(5): 1134-1136. DOI: 10.3969/j.issn.1001-5256.2022.05.033

Abstract(671)

HTML (112)

PDF (3096KB)(33)

Abstract:

Reviews

Research advances in intestinal flora and the development and prognosis of chronic hepatitis B

Ziwei GUO, Jiaxin ZHANG, Shuo LI, Xiaobin LI, Shun ZHU, Qian JIN, Xiaoke LI, Yongan YE

2022, 38(5): 1137-1142. DOI: 10.3969/j.issn.1001-5256.2022.05.034

Abstract(804)

HTML (299)

PDF (1908KB)(93) Cited By (6)

Abstract:
Intestinal flora is closely associated with chronic hepatitis B (CHB). Recent studies have shown that the imbalance of intestinal flora is associated with the development, progression, and prognosis of CHB, and the environment of intestinal flora may also change with disease progression, suggesting ...

Research advances in the role of gut microbiota in chronic hepatitis B, chronic hepatitis C, and related liver diseases

Hui DENG, Bin ZHANG, Bin ZHU, Zhayier DILIHUMAER, Weixian WANG, Chunxia GUO, Dongliang YANG, Xin ZHENG, Junzhong WANG, Baoju WANG

2022, 38(5): 1143-1147. DOI: 10.3969/j.issn.1001-5256.2022.05.035

Abstract(816)

HTML (265)

PDF (1968KB)(80) Cited By (7)

Abstract:
Hepatitis B virus infection and hepatitis C virus infection often progress to end-stage liver diseases such as liver cirrhosis, liver failure, and hepatocellular carcinoma, which endanger the life of patients. Recent studies have shown that gut microbiota are closely associated with chronic viral li...

Role and mechanism of interleukin-35 in hepatitis B virus-related diseases

Xiaofei YANG, Jianqi LIAN, Ye ZHANG

2022, 38(5): 1148-1151. DOI: 10.3969/j.issn.1001-5256.2022.05.036

Abstract(692)

HTML (209)

PDF (2196KB)(57)

Abstract:
Interleukin-35 (IL-35) is an immunosuppressive cytokine mainly secreted by regulatory T cells and regulatory B cells and is involved in the pathogenesis of infectious diseases, tumors, and autoimmune diseases. This article summarizes the immunoregulatory role and mechanism of IL-35 in hepatitis B, l...

Mechanism of ferroptosis in the formation of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Minghao LIU, Sutong LIU, Lihui ZHANG, Yajiao GU, Dongfang SHANG, Zhun XIAO, Wenxia ZHAO

2022, 38(5): 1152-1155. DOI: 10.3969/j.issn.1001-5256.2022.05.037

Abstract(1181)

HTML (2356)

PDF (2497KB)(259) Cited By (13)

Abstract:
Ferroptosis is a type of iron-dependent cell death driven by lipid peroxidation, and its mechanism is associated with iron homeostasis imbalance, lipid peroxidation, and slC7A11-GSH-GPX4 antioxidant system. Ferroptosis plays a key role in the development and progression of nonalcoholic fatty liver d...

Role of exercise-induced autophagy in prevention and treatment of nonalcoholic fatty liver disease

Yuesheng LIAO, Lili BAI

2022, 38(5): 1156-1160. DOI: 10.3969/j.issn.1001-5256.2022.05.038

Abstract(823)

HTML (261)

PDF (2114KB)(55) Cited By (2)

Abstract:
Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease characterized by chronic liver damage. Epidemiological surveys have shown that the incidence rate of NAFLD is increasing constantly and NAFLD has become a serious threat to human life and health. Studies have shown that autophagy dysreg...

Research advances in hepatic fibrosis related signal pathways and anti-hepatic fibrosis drugs

Suriguga LU, Ting LIU, Dandan ZHU, Sijia YU, Liqing LU, Junjie DING

2022, 38(5): 1161-1164. DOI: 10.3969/j.issn.1001-5256.2022.05.039

Abstract(997)

HTML (917)

PDF (2927KB)(122) Cited By (15)

Abstract:
Hepatic fibrosis is a pathological process in which the liver is subjected to various acute and chronic injuries for a long time, resulting in activation of hepatic stellate cells, the imbalance between the production and degradation of extracellular matrix, and the deposition of extracellular matri...

Effect of different antiviral drugs in reducing the risk of hepatitis B virus-related hepatocellular carcinoma

Lixian WU, Weiqiang ZHENG, Huanqin HAN

2022, 38(5): 1165-1168. DOI: 10.3969/j.issn.1001-5256.2022.05.040

Abstract(775)

HTML (164)

PDF (1886KB)(89) Cited By (1)

Abstract:
Antiviral therapy can reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B. As for the first-line antiviral drugs, more studies have shown that tenofovir disoproxil fumarate may be better than entecavir in reducing the risk of HCC, especially among Asian patients; a...

Research advances in animal models of Wilson's disease

Yulong YANG, Taohua WEI, Wenming YANG, Wenjie HAO, Yue YANG, Nannan QIAN, Xiang LI, Hailin JIANG

2022, 38(5): 1169-1174. DOI: 10.3969/j.issn.1001-5256.2022.05.041

Abstract(1131)

HTML (205)

PDF (1905KB)(114) Cited By (4)

Abstract:
Wilson's disease (WD) is a rare autosomal recessive disorder with a complex pathogenesis involving multiple systems, multiple visceral organs, and the complex copper homeostasis regulation system within the body. The liver is the most common organ for copper deposition, and liver injury is the earli...

Role of thymic stromal lymphopoietin in liver diseases

Wenshang CHEN, Jijin ZHU, Shilai LI

2022, 38(5): 1175-1178. DOI: 10.3969/j.issn.1001-5256.2022.05.042

Abstract(977)

HTML (170)

PDF (1896KB)(48) Cited By (2)

Abstract:
Thymic stromal lymphopoietin (TSLP) is a type I interleukin 2 family cytokine composed of four short-chain α-helix bundles and has homology with interleukin-7. TSLP plays an important role in many allergic diseases or autoimmune diseases, such as asthma, atopic dermatitis, eosinophilic esophagitis, ...

Research advances in sodium taurocholate cotransporting polypeptide in hepatobiliary diseases

Xiaoqiang GAO, Shi ZUO, Xiaodong JIA, Yinying LU

2022, 38(5): 1179-1182. DOI: 10.3969/j.issn.1001-5256.2022.05.043

Abstract(1481)

HTML (641)

PDF (2054KB)(103)

Abstract:
Sodium taurocholate cotransporting polypeptide (NTCP) is not only an important transporter for bile acid absorption into the liver, but also a functional receptor for HBV and HDV, and extensive studies have been performed for its structure, function, gene characteristics, and expression and regulati...

Risk factors for herb-induced liver injury

Yan YANG, Feilin GE, Qian HUANG, Rui ZENG, Xinyue ZHANG, Qin SUN

2022, 38(5): 1183-1187. DOI: 10.3969/j.issn.1001-5256.2022.05.044

Abstract(915)

HTML (286)

PDF (1903KB)(103) Cited By (11)

Abstract:
Drug-induced liver injury (DILI) is one of the common adverse drug reactions and is the main cause of withdrawal of drugs after marketing, which has attracted more and more attention of the public, and herb-induced liver injury (HILI) is a special type of DILI. In recent years, the frequent occurren...

Advances in the clinical research on liver transplantation in treatment of acute-on-chronic liver failure

Jiang LI, Xing DAI, Dazhi TIAN, Wentao JIANG, Zhongyang SHEN

2022, 38(5): 1188-1191. DOI: 10.3969/j.issn.1001-5256.2022.05.045

Abstract(863)

HTML (136)

PDF (1897KB)(49) Cited By (3)

Abstract:
Acute-on-chronic liver failure (ACLF) is a disease of rapid deterioration of liver function caused by the acute exacerbation of chronic liver diseases, and it is often associated with multiple organ failure and has a poorer prognosis than common liver cirrhosis. Many studies suggest that timely live...

Early predictors for acute kidney injury in acute pancreatitis

Yan WANG, Mingzheng LI, Yufeng LIU, Shiming WANG

2022, 38(5): 1192-1197. DOI: 10.3969/j.issn.1001-5256.2022.05.046

Abstract(1041)

HTML (324)

PDF (1924KB)(74) Cited By (13)

Abstract:
Acute pancreatitis (AP) is one of the common acute abdominal diseases of the digestive system, and early treatment to avoid aggravation to severe pancreatitis (SAP) is the key to guaranteeing prognosis. AP with acute kidney injury (AKI) can significantly increase the mortality rate of pancreatitis. ...

Research advances in abnormal activation and secretion of pancreatic enzymes in acute pancreatitis

Tianyu CUI, Ruixia LIU, Chenghong YIN

2022, 38(5): 1198-1202. DOI: 10.3969/j.issn.1001-5256.2022.05.047

Abstract(757)

HTML (233)

PDF (2620KB)(55) Cited By (13)

Abstract:
Abnormal activation and secretion of pancreatic enzymes in pancreatic acinar cells is one of the important pathogeneses of acute pancreatitis (AP) and can directly damage the pancreatic tissue to accelerate disease progression and induce severe AP. At present, the drugs inhibiting the abnormal activ...

Role of cancer-associated fibroblasts in drug resistance of pancreatic cancer

Yi YAN, Junmei JIA, Yarong GUO

2022, 38(5): 1203-1208. DOI: 10.3969/j.issn.1001-5256.2022.05.048

Abstract(1152)

HTML (413)

PDF (3024KB)(91) Cited By (4)

Abstract:
Pancreatic cancer is one of the fatal malignant tumors, and its dense stroma, which accounts for 90% of the volume of pancreatic tumor, is the main reason for the low survival rate of pancreatic cancer. Cancer-associated fibroblasts (CAFs) are an important group of cells in the tumor stroma of pancr...